Journal
ONCOTARGET
Volume 1, Issue 1, Pages 34-42Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.106
Keywords
acute myeloid leukemia; azacitidine; valproic acid; ATRA; FZD9 methylation
Categories
Funding
- Celgene
- Celgene (Paris, France)
- Roche (Neuilly/Seine, France)
- Celgene (Boudry, Switzerland)
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- Direction de l'Hospitalisation et de l'Organisation des Soins (DHOS) from the French Government
- Region Ile-de-France
- Fondation de France
Ask authors/readers for more resources
In this Phase 2 study, we evaluated the efficacy of combination of 5-azacitidine (AZA), valproic acid (VPA), and all-trans retinoic acid (ATRA) in patients with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Treatment consisted of six cycles of AZA and VPA for 7 days, followed by ATRA for 21 days. Sixty-five patients were enrolled (median age, 72 years; 55 AML including 13 relapsed/refractory patients, 10 MDS; 30 unfavorable karyotypes). Best responses included 14 CR and 3 PR (26%), 75% of the responders and 36% of the non-responders achieving an erythroid response. Median overall survival (OS) was 12.4 months. Untreated patients had a longer OS than relapsed/refractory patients. In patients who fulfilled the 6 planned cycles, OS did not appear to depend on CR/PR achievement, suggesting that stable disease while on-treatment would be a surrogate for survival with this approach. During therapy, early platelet response and demethylation of the FZD9, ALOX12, HPN, and CALCA genes were associated with clinical response. Finally, there was no evidence for the restoration of an ATRA-induced differentiation during therapy. Epigenetic modulation deserves prospective comparisons to conventional care in patients with high-risk AML, at least in those presenting previously untreated disease and low blast count.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available